Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...
Longer treatment with an Akero Therapeutics drug in development for the liver disease MASH led to better results, including improvement in fibrosis, the liver scarring that is a hallmark of the ...
Metabolic dysfunction-associated steatohepatitis (MASH), formally known as nonalcoholic steatohepatitis (NASH), is a liver disease that develops when accumulated liver fat causes inflammation and ...
Panelists discuss how metabolic dysfunction drives liver injury, highlighting early recognition of the obesity–MASH connection as key to prevention. Panelists discuss how obesity and insulin ...
Elevated deoxycholic acid, triacylglycerols, ceramides, and phospholipids were identified in MASH patients, suggesting a noninvasive diagnostic potential. The study used untargeted lipidomic analysis ...
"[We] have conducted a large individual participant data meta-analysis and shown that screening strategies using sequential application of simple NITs like FIB-4 or NFS followed by LSM-VCTE achieve ...
Please provide your email address to receive an email when new articles are posted on . Researchers recommended the FibroScan-AST score to target those at risk for MASH. The score should be used with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results